Francisco Marty, MD, Dana-Farber Cancer Institute, discusses the initial results of the Phase III trial evaluating letermovir for CMV after bone marrow transplant.
Francisco Marty, MD
Advertisement
Articles by Francisco Marty, MD
Advertisement
Latest Updated Articles
Dr. Marty on Letermovir for CMV Prevention After Stem Cell TransplantPublished: February 26th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5